Century Therapeutics Inc’s filing revealed that its President and CEO Pfeiffenberger Brent unloaded Company’s shares for reported $27179.0 on Feb 18 ’25. In the deal valued at $0.78 per share,34,712 shares were sold. As a result of this transaction, Pfeiffenberger Brent now holds 1,192,545 shares worth roughly $0.73 million.
Then, Pfeiffenberger Brent bought 34,712 shares, generating $27,166 in total proceeds.
Before that, Farid Adrienne sold 1,054 shares. Century Therapeutics Inc shares valued at $822 were divested by the Chief Operations Officer at a price of $0.78 per share. As a result of the transaction, Farid Adrienne now holds 134,076 shares, worth roughly $81786.36.
Rodman & Renshaw initiated its Century Therapeutics Inc [IPSC] rating to a Buy in a research note published on August 08, 2024; the price target was $6. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in late August from “an Overweight” to “a Neutral”. Chardan Capital Markets began covering IPSC with “Buy” recommendation on December 27, 2022. Guggenheim started covering the stock on October 31, 2022. It rated IPSC as “a Buy”.
Price Performance Review of IPSC
On Tuesday, Century Therapeutics Inc [NASDAQ:IPSC] saw its stock fall -1.43% to $0.61. Over the last five days, the stock has lost -13.80%. Century Therapeutics Inc shares have fallen nearly -40.09% since the year began. Nevertheless, the stocks have fallen -83.51% over the past one year. While a 52-week high of $5.51 was reached on 01/08/25, a 52-week low of $0.60 was recorded on 03/04/25. SMA at 50 days reached $0.8686, while 200 days put it at $1.6975.
Levels Of Support And Resistance For IPSC Stock
The 24-hour chart illustrates a support level at 0.5651, which if violated will result in even more drops to 0.5251. On the upside, there is a resistance level at 0.6463. A further resistance level may holdings at 0.6875. The Relative Strength Index (RSI) on the 14-day chart is 21.03, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0777, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.83%. Stochastics %K at 15.82% indicates the stock is a buying.
The most recent change occurred on October 10, 2022 when Canaccord Genuity began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
